Asia Pacific Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

  • Product Code:
    RP-ID-10334459
  • Published Date:
    21 Oct 2022
  • Region:
    Global
  • Pages:
    126
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-26

Impact Analysis on the Growth of Market

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

..

..

The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

Translate Report

Asia Pacific oral antibiotics market will grow by 4.6% annually with a total addressable market cap of $103.3 billion over 2020-2030 owing to the rising infection complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.
Highlighted with 35 tables and 62 figures, this 126-page report “Asia Pacific Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country.

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cephalosporin
• Cefuroxime Axetil
• Cephalexin
• Cefixime
• Cefpodoxime
• Other Cephalosporin
Penicillin
Macrolides
Tetracycline
Quinolones
Sulfonamides
Aminoglycosides
Other Drug Classes

Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms

Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics

Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Urinary Tract Infections (UTIS)
• Upper Respiratory Tract Infections (URTI)
• Lower Respiratory Tract Infections (LRTIs)
Dental Infections
• Monotherapies
• Combined Therapies
Respiratory Tract Infections (RTIS)
Other Applications

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Brand Antibiotics
• Generic Antibiotics

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific oral antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports

-->